CN119487061A - 具有半衰期延长结构域的融合蛋白 - Google Patents

具有半衰期延长结构域的融合蛋白 Download PDF

Info

Publication number
CN119487061A
CN119487061A CN202380050753.0A CN202380050753A CN119487061A CN 119487061 A CN119487061 A CN 119487061A CN 202380050753 A CN202380050753 A CN 202380050753A CN 119487061 A CN119487061 A CN 119487061A
Authority
CN
China
Prior art keywords
seq
protein
amino acid
fusion protein
mutein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380050753.0A
Other languages
English (en)
Chinese (zh)
Inventor
乌尔里希·豪普茨
伊瓦·博塞-德内克
格雷戈尔·霍夫曼
马尼亚·格洛泽-布罗伊尼格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Navigo Proteins GmbH
Original Assignee
Scil Proteins GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scil Proteins GmbH filed Critical Scil Proteins GmbH
Publication of CN119487061A publication Critical patent/CN119487061A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202380050753.0A 2022-06-30 2023-06-30 具有半衰期延长结构域的融合蛋白 Pending CN119487061A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22182401 2022-06-30
EP22182401.4 2022-06-30
EP22205669 2022-11-04
EP22205669.9 2022-11-04
PCT/EP2023/068109 WO2024003393A1 (en) 2022-06-30 2023-06-30 Fusion proteins with half life extending domains

Publications (1)

Publication Number Publication Date
CN119487061A true CN119487061A (zh) 2025-02-18

Family

ID=87136437

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380050753.0A Pending CN119487061A (zh) 2022-06-30 2023-06-30 具有半衰期延长结构域的融合蛋白

Country Status (7)

Country Link
US (1) US20250388696A1 (https=)
EP (1) EP4547708A1 (https=)
JP (1) JP2025525305A (https=)
CN (1) CN119487061A (https=)
AU (1) AU2023301542A1 (https=)
CA (1) CA3253055A1 (https=)
WO (1) WO2024003393A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025125378A1 (en) * 2023-12-12 2025-06-19 Navigo Proteins Gmbh Novel serum albumin-binding fusion proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1208155A1 (en) * 2012-03-28 2016-02-26 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
US11414466B2 (en) * 2017-11-07 2022-08-16 Navigo Proteins Gmbh Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
JP7611173B2 (ja) * 2019-06-04 2025-01-09 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換えｆａｐ結合タンパク質及びそれらの使用
EP4161954B1 (en) * 2020-07-16 2023-11-01 Navigo Proteins Gmbh Serum stable binding proteins for human her2 for theranostic applications

Also Published As

Publication number Publication date
WO2024003393A1 (en) 2024-01-04
US20250388696A1 (en) 2025-12-25
JP2025525305A (ja) 2025-08-05
EP4547708A1 (en) 2025-05-07
CA3253055A1 (en) 2024-01-04
AU2023301542A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
JP7498971B2 (ja) がん診断及び治療のための新規ｐｓｍａ特異的結合タンパク質
JP2026031936A (ja) 線維芽細胞活性化タンパク質（ｆａｐ）のための特異的結合性分子
KR20210104106A (ko) 암 진단 및 치료를 위한 신규 folr1 특이적 결합 단백질
US20250388696A1 (en) Fusion proteins with half life extending domains
WO2025125378A1 (en) Novel serum albumin-binding fusion proteins
EP4326749A1 (en) Novel human programmed death ligand 1 (pd-l1) specific binding molecules
EP4161954B1 (en) Serum stable binding proteins for human her2 for theranostic applications
AU2024401183A1 (en) Novel serum albumin-binding fusion proteins
JP2025534423A (ja) プログラム死リガンド１（ｐｄ－ｌ１）に対して高い結合親和性を有する新規タンパク質
WO2026022338A1 (en) Specific binding proteins for human erb-b3 receptor tyrosine kinase 3 (her3)
CN118317972A (zh) 成纤维细胞活化蛋白（fap）的特异性结合分子

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination